tbuckley/cabot-search huggingface dataset:
High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study
Authors: Seamus P. Whelton, John W. McEvoy, Mariana Lazo, Josef Coresh, Christie M. Ballantyne, Elizabeth Selvin
Journal: Diabetes Care (2016)

OBJECTIVE Many individuals with prediabetes have evidence of subclinical myocardial damage and are at an increased risk of cardiovascular disease (CVD). If subclinical myocardial damage is independently associated with incident diabetes, this may contribute to the understanding of the association between diabetes and CVD. This study was conducted to determine whether high-sensitivity cardiac troponin T (hs-cTnT) is associated with incident diabetes. RESEARCH DESIGN AND METHODS Using Kaplan-Meier curves and Cox models, we prospectively analyzed 8,153 participants without known diabetes or CVD. We used the Harrell C statistic to investigate whether hs-cTnT added incremental prognostic information for diabetes prediction. RESULTS During a median of 13 years of follow-up, there were 1,830 incident cases of diagnosed diabetes. After adjustment for demographics and traditional risk factors, participants with a baseline hs-cTnT of 9–13 ng/L or ≥14 ng/L had a significantly increased risk for diabetes compared to those with an hs-cTnT of ≤5 ng/L, with hazard ratios of 1.14 (95% CI 0.99–1.33) and 1.25 (95% CI 1.03–1.53), respectively (P = 0.018 for trend). Linear spline modeling that included adjustment for baseline fasting glucose suggested an increased risk of incident diabetes for participants with hs-cTnT levels &amp;gt;8 ng/L. Furthermore, the addition of hs-cTnT to fully adjusted models that included glucose significantly improved the prediction of incident diabetes from 0.7636 to 0.7644 (P = 0.023). CONCLUSIONS Participants with elevated hs-cTnT levels at baseline had an increased risk of incident diabetes, suggesting that the measurement of hs-cTnT may incorporate an underlying pathophysiologic overlap between diabetes and CVD not captured by other traditional risk factors. Measurement of hs-cTnT may be useful to identify individuals at an increased risk for incident diabetes and CVD in order to provide early and more intensive risk factor modification.
Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy
Authors: Raphaela Freidl, Antonia Gstoettner, Ulrike Baranyi, Ines Swoboda, Frank Stolz, Margarete Focke-Tejkl, Thomas Wekerle, Ronald van Ree, Rudolf Valenta, Birgit Linhart
Journal: Journal of Allergy and Clinical Immunology (2016)

Fish is a frequent elicitor of severe IgE-mediated allergic reactions. Beside avoidance, there is currently no allergen-specific therapy available. Hypoallergenic variants of the major fish allergen, parvalbumin, for specific immunotherapy based on mutation of the 2 calcium-binding sites have been developed.This study sought to establish a mouse model of fish allergy resembling human disease and to investigate whether mouse and rabbit IgG antibodies induced by immunization with a hypoallergenic mutant of the major carp allergen protect against allergic symptoms in sensitized mice.C3H/HeJ mice were sensitized with recombinant wildtype Cyp c 1 or carp extract by intragastric gavage. Antibody, cellular immune responses, and epitope specificity in sensitized mice were investigated by ELISA, rat basophil leukemia assay, T-cell proliferation experiments using recombinant wildtype Cyp c 1, and overlapping peptides spanning the Cyp c 1 sequence. Anti-hypoallergenic Cyp c 1 mutant mouse and rabbit sera were tested for their ability to inhibit IgE recognition of Cyp c 1, Cyp c 1-specific basophil degranulation, and Cyp c 1-induced allergic symptoms in the mouse model.A mouse model of fish allergy mimicking human disease regarding IgE epitope recognition and symptoms as close as possible was established. Administration of antisera generated in mice and rabbits by immunization with a hypoallergenic Cyp c 1 mutant inhibited IgE binding to Cyp c 1, Cyp c 1-induced basophil degranulation, and allergic symptoms caused by allergen challenge in sensitized mice.Antibodies induced by immunization with a hypoallergenic Cyp c 1 mutant protect against allergic reactions in a murine model of fish allergy.
Massively Parallel Immunoglobulin Gene Sequencing Provides Ultra-Sensitive Minimal Residual Disease Detection and Predicts Post-Transplant Relapse in Acute Lymphoblastic Leukemia by Three to Six Months,
Authors: Aaron C. Logan, Nikita Vashi, Malek Faham, Victoria Carlton, Ismael Buno, Jianbiao Zheng, Martin Moorhead, Mark Klinger, Tom Willis, Melody B. Zhang, Amna Waqar, James L. Zehnder, David B. Miklos
Journal: Blood (2011)
Temporary Transfer of Firearms From the Home to Prevent Suicide
Authors: Alexander D. McCourt, Jon S. Vernick, Marian E. Betz, Sara Brandspigel, Carol W. Runyan
Journal: JAMA Internal Medicine (2016)

The presence of firearms in the home increases the risk of suicide for residents. As a result, clinicians and professional organizations recommend counseling about temporary removal of firearms from the home of potentially suicidal individuals. In some states, however, firearm laws may affect the ability to easily transfer a gun temporarily to reduce suicide risk. In particular, universal background check (UBC) laws-which require a background check whenever a gun is transferred, even by non-gun dealers-may also apply to temporary transfers intended to reduce suicide risk. Clinicians have previously reported that confusion regarding state firearm laws and uncertainty over the legality of a temporary transfer have affected their ability to effectively counsel patients. We summarize the laws of all 50 states and specifically examine the relevant firearm laws of 3 representative states with UBCs and different approaches-Maryland, Colorado, and California. We identify both helpful and problematic aspects of state laws regarding temporary transfer of firearms. We provide recommendations for amending UBC laws to make it easier for clinicians and patients to temporarily transfer firearms.
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
Authors: Antonio Palumbo, Alessandra Larocca, Vittorio Montefusco, Davide Rossi, Angelo Michele Carella, Roberto Mina, Claudia Crippa, Mariella Sciacca, Monica Galli, Delia Rota Scalabrini, Magda Marcatti, Tommasina Guglielmelli, Nicola Giuliani, Giacinto La Verde, Ileana Baldi, Vittorio Emanuele Muccio, Mario Boccadoro, Paolo Corradini
Journal: Blood (2012)
A Polymerase Chain Reaction-Based Method to Detect Gene-Specific Adducts Induced by Anticancer Drugs. Clinical Application in Multiple Myeloma.
Authors: Meletios A. Dimopoulos, Christine Liakos, Hara G. Episkopou, Dimitra T. Stefanou, Soterios A. Kyrtopoulos, Petros P. Sfikakis, Evangelos Terpos, Aristotelis Bamias, Vassilis L. Souliotis
Journal: Blood (2009)
FRI0090 BMI and Tender Joints Are Predictors of Not Reaching Sustained Remission in Patients Participating in An Aggressive Treat-To-Target Study: Table 1.
Authors: N.P. Sundlisater, S. Lillegraven, A.-B. Aga, I.C. Olsen, T. Uhlig, H.B. Hammer, D. van der Heijde, T.K. Kvien, E.A. Haavardsholm
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Modern rheumatoid arthritis (RA) care is based on early DMARD initiation, tight control and treat-to-target strategies aiming for abrogation of inflammation to optimize long term outcomes. However, even in the most aggressive treatment studies a substantial proportion of patients do not reach sustained remission. <h3>Objectives</h3> We aimed to identify predictors of not reaching sustained DAS remission in early RA patients followed by a treat-to-target algorithm with pre-specified DMARD adjustments. <h3>Methods</h3> RA patients who fulfilled the ACR/EULAR 2010 classification criteria, with &lt;2 years from first swollen joint and who were DMARD naïve with indication for DMARD treatment were included in the ARCTIC trial between 2010 and 2013. Patients were followed by a structured tight control algorithm aiming for a target of DAS&lt;1.6 and no swollen joints, and in half the patients the treatment target also included no joints with ultrasound power-Doppler signal. For patients with established risk factors for joint destruction (ACPA or RF positive with radiographic erosions or MRI bone marrow edema at baseline) treatment could be escalated more rapidly to biologic therapy. Data collection included 44 SJC, Ritchie articular index (RAI), laboratory tests, patient reported outcomes, ultrasound examination and radiographs. Multivariate logistic regression was used to assess the associations between baseline variables and not being in sustained DAS remission at 16 to 24 months. A univariate p-value of &lt;0.25 was used for variable selection, and a p-value of &lt;0.05 to keep the variable in the model. Patient reported physical function and physician global were not included in the model building because of collinearity. <h3>Results</h3> A total of 221 patients were included, with mean [SD] age 51.1 [13.7] years, disease duration 7.2 [5.4] months, DAS 3.5 [1.2]. 63% were female, 72% RF- and 82% ACPA positive, and 16% escalated treatment more rapidly to biologic therapy. 103 (47%) did not reach sustained DAS remission between 16 and 24 months. Tender joints assessed by RAI (OR 1.11 per unit, p&lt;0.001) and BMI (OR 1.07 per unit, p=0.046) were independent predictors for not reaching sustained DAS remission. <h3>Conclusions</h3> In early RA patients treated by an aggressive treat-to-target strategy, tender joints assessed by Ritchie articular index and BMI at time of diagnosis were independent predictors for not reaching sustained DAS remission. Our results are supported by previous studies indicating that overweight decreases the chance of achieving treatment success in early RA (1). <h3>References</h3> Sandberg ME et al. ARD 2014;73(11):2029–33. <h3>Disclosure of Interest</h3> None declared
SAT0482 Risk Factors for Severe Infection and Outcome of Secondary Hypogammaglobulinaemia in Patients with Autoimmune Rheumatic Diseases Treated with Rituximab: Preliminary Results from 400 Patients at A Single Centre: Table 1
Authors: M.Y. Md Yusof, E.M. Hensor, S. Das, E.M. Vital, P. Emery, S. Savic
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rituximab (RTX) is used in various autoimmune rheumatic diseases (AIRDs) that are refractory to standard therapies. Attrition of long-lived plasma cells and hypogammaglobulinaemia may occur with repeat cycles of therapy leading to serious infection. <h3>Objectives</h3> To evaluate risk factors for severe infection and assess outcome of secondary hypogammaglobulinaemia during RTX treatment in AIRDs. <h3>Methods</h3> We conducted a retrospective observational study of all patients with AIRDs treated with RTX at a single centre.Each cycle of RTX consisted of 2x1000mg infusions repeated on clinical relapse. IgM, IgA and IgG levels were measured at baseline and 6 months after each cycle. Baseline factors for association with serious infection within 12 months of a RTX cycle were tested using univariate (UVA) and multivariate (MVA) logistic regression analyses. <h3>Results</h3> The first 400 consecutive patients from a total cohort of 800 were analysed. 254 (63%) had RA, 88 (22%) SLE, 47 (12%) AAV, 6 (1.5%) DM, 3 APS (1%) and 2 (0.5%) SSc. Total follow-up: 1650.3 patient-years. There were 166 serious infections recorded in 101 patients; 135 in 88 within 12 months of a cycle (8.1/100 patient years). Rates were lower in connective tissue disease (6.5) than RA (9.4). In MVA, previous severe infection, corticosteroids and low IgG were significantly associated with increased risk of serious infection. Ig data were available in 375 (94%) patients. At RTX initiation, 23 (6%) patients had low IgG (normal range 6–16 g/L). Following RTX treatment, 18 remained low, 3 returned to normal and 15 had developed new low IgG. 6 patients required Ig replacement due to recurrent serious infections related to low IgG. <h3>Conclusions</h3> We have identified risk factors for serious infection at RTX initiation including previous serious infection, concomitant corticosteroids and low IgG. Most hypogammaglobulinaemia persisted with subsequent treatment thus highlighting the need for Ig monitoring. Further analysis of changes in Ig levels and infection in repeat cycles is in progress and can be used to develop guidelines for safety monitoring of rituximab. <h3>Acknowledgement</h3> Dr John Baptiste Candelier, Lt Kol Dr Hatem and Huma Cassamoali <h3>Disclosure of Interest</h3> M. Y. Md Yusof: None declared, E. M. Hensor: None declared, S. Das: None declared, E. M. Vital Grant/research support from: Roche, GSK, P. Emery Grant/research support from: Abbott, BMS, Pfizer, MSD and Roche., Consultant for: BMS, Abbott, Pfizer, MSD, Novartis, Roche and UCB, S. Savic: None declared
SP0172 Glucocorticoid-Induced Complications in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Authors: F. Buttgereit
Journal: Annals of the Rheumatic Diseases (2016)

With over 60 years of experience with glucocorticoids (GC), the number of patients treated and the range of clinical applications is more extensive than with other treatments. GC are still widely used in clinical medicine today, and they form a mainstay of therapy for polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) since they are cost-effective drugs which exert strong anti-inflammatory and immunosuppressive. However, there is increasing awareness of the potential for these drugs to produce adverse effects. Especially if higher dosages have to be given over longer periods of time, cardiovascular, gastrointestinal, dermatological, ophthalmological, and metabolic adverse effects, an increased risk of infection, the incidence of a Cushingoid phenotype, and in particular GC-induced osteoporosis (GIOP) are to be mentioned. The available data describing frequency and severity of these adverse effects are fragmentary. For example, it is difficult to distinguish specific adverse effects of a GC therapy from other causations (e. g., the treated disease itself, other concomitant diseases or concomitant therapies). Therefore, as a general rule, also in PMR and GCA as much GC as necessary, but as little as possible should be administered. Recommendations and guidelines have been developed describing in detail suggested approaches for using GC in induction therapy, during initial and further tapering until discontinuation, and flare management. It should be noted however, that these algorithms base upon expert opinion and assessment of the literature, but they have not been formally tested in randomized controlled trials. Treatment of PMR and GCA is usually required for 1–3 years, but frequently also longer and often with daily GC doses around 5 mg prednisone equivalent. Therefore, a recent publication of a EULAR Task Force is important since it reports the risk of harm to be low for the majority of patients at long-term dosages of ≤5mg prednisone equivalent per day, whereas at dosages of &gt;10mg/d the risk of harm is elevated. At dosages between &gt;5 and ≤10mg/d, patient-specific characteristics including protective and/or risk factors need consideration when estimating the risk of harm. <h3>Disclosure of Interest</h3> F. Buttgereit Grant/research support from: Horizon Pharma, Consultant for: Horizon Pharma, Mundipharma, Pfizer, Speakers bureau: Horizon Pharma, Mundipharma, Pfizer
TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.
Authors: Carolina Sandler, David Goldstein, Sarah Horsfield, Barbara Kaye Bennett, Michael Friedlander, Patricia A. Bastick, Craig R. Lewis, Eva Segelov, Frances M. Boyle, Melvin T.M. Chin, Benjamin K Barry, Kate Webber, Andrew R. Lloyd
Journal: Journal of Clinical Oncology (2015)

9571 Background: Cancer related fatigue is prevalent and disabling. When persistent and unexplained, it is termed post-cancer fatigue (PCF). Cognitive behavioural therapy (CBT) and graded exercise therapy (GET) may improve symptoms and functional outcomes. Methods: A randomised control trial - Treatment of Post-cancer fatigue Study (TOPS) assigned patients to an education intervention, or a 12 week integrated CBT and GET intervention supervised by an exercise physiologist and clinical psychologist. Three months post treatment for breast or colon cancer, eligible patients had: clinically-significant fatigue; no co-morbid medical or psychiatric conditions which explained the fatigue; and no clinical or laboratory evidence of cancer recurrence. The education arm included a single visit with clinicians describing the principles of CBT/GET and an education booklet. The CBT/GET arm included fortnightly individually tailored consultations. The primary outcome measures were self-reported fatigue (SOMA subscale - SPHERE questionnaire; (0 – 12)) and functional status (Role limitation due to physical health problems – SF36 questionnaire (0 – 100)) comparing baseline, end treatment (12 weeks), and follow-up (24 weeks). Outcomes were analysed by 'clinically-significant' improvement designated a priori as ≥ one standard deviation improvement in fatigue scores. Results: 160 patients were screened, and 34% (n = 55) were eligible. The primary reason for ineligibility was sub-threshold fatigue (n = 61, 58%). 46 patients were enrolled, including 43 women (94%), with a mean age of 51 years. Intention-to-treat analysis showed that fatigue severity improved in all enrolled subjects improved from a mean of 5.2 ± 3.1 to 3.9 ± 2.8 at week 12, suggesting a natural history of improvement. Clinically significant improvement was observed in 7 of 22 subjects in the intervention group compared to 2 of 24 in the education group (p < 0.05, χ2). These subjects had a mean improvement in functional status (SF-36) of 25.4 ± 33.3 compared to non-responders (6.0 ± 15.3, p < 0.01, t test). Conclusions: Combined CBT/GET improves fatigue and functional outcomes for a subset of patients with PCF. Further studies to improve the response rate are warranted. Clinical trial information: ACTRN12611000338965.
Aldehyde Dehydrogenases Play a Role in Acute Myeloid Leukemia and Have Prognostic and Therapeutic Significance
Authors: Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, Daniel A. Pollyea, Vasilis Vasiliou, R. Keith Humphries, Craig T. Jordan, Clayton A. Smith
Journal: Blood (2014)
PTU-056 Outcomes of Emergency Admissions with Crohn’s Disease in Adults in England Between 2004 and 2014
Authors: JG Rees, J Mytton, F Evison, P Patel, N Trudgill
Journal: Gut (2016)

<h3>Introduction</h3> Between 2006 and 2010, the UK national audit of adult inflammatory bowel disease admissions revealed a small but non-significant fall in mortality in Crohn’s disease (CD) from 1.3 to 0.8%, an increase in the rate of prescription of anti-TNF therapy on admission from 3.9 to 8% and a fall in surgery from 23 to 18%. <h3>Methods</h3> Using Hospital Episode Statistics, patients aged between 18 and 60 years coded with a first emergency admission with CD were identified. The influence of demographic factors, comorbidity and infused anti-TNF therapy on mortality, surgery and emergency readmissions was examined using multivariate logistic regression. <h3>Results</h3> Between 2004 and 2014, 24,830 patients (55% female, mean age of 35 (IQR 25–44)). Mortality was 0.22% at 30 days, 0.29% in hospital and 0.81% within 1 year. During admission, 19.2% of patients underwent surgery (median time to surgery 2 days (IQR 1–6)) and 1.9% received infused anti-TNF therapy. Surgery during admission rose from 16.1 to 22.9% (OR 1.52 (95% CI 1.32–1.75) p &lt; 0.001) between 2004 and 2014, and infused anti-TNF therapy rose from 1.8 to 2.8% between 2006 and 2014. In-hospital and 1 year mortality fell from 0.51 and 1.03% in 2004 to 0.10 and 0.57% in 2013 (0.18 (95% CI 0.04–0.77) p = 0.021 and 0.46 (0.23–0.91) p = 0.026 respectively). Patients aged 35–60 had a higher 30 day (3.99 (1.97–8.05) p &lt; 0.001) and 1 year mortality (4.57 (3.14–6.65) p &lt; 0.001) than those aged 18–34. Increasing comorbidity (15.38 (7.33–32.23) p &lt; 0.001) and deprivation (3.14 (1.06–9.31) p = 0.039) was associated with a higher 30 day and 1 year mortality, but not gender. Females were less likely to have surgery during their admission (0.71 (0.67–0.76) p &lt; 0.001) or within 1 year (0.82 (0.77–0.97) p &lt; 0.001) and surgery within 1 year was more common in younger (35–60 years 0.87 (0.81–0.93) p &lt; 0.001) and non-white patients (1.18 (1.08–1.28) p &lt; 0.001). Anti-TNF therapy during admission was associated with less surgery immediately (0.39 (0.28–0.54) p &lt; 0.001) and within 1 year (0.55 (0.41–0.73) p &lt; 0.001). Emergency readmissions within 30 days were associated with male gender (females 0.74 (0.55–0.98) p 0.039), younger age (35–60 years 0.85 (0.79–0.91) p &lt; 0.001), non-white ethnicity (1.25 (1.13–1.38) p &lt; 0.001) and not having anti-TNF therapy during admission (0.74 (0.55–0.98) p0.039). <h3>Conclusion</h3> For patients with a first emergency admission for CD, in-hospital and 1 year mortality fell considerably over the study period. Surgery and anti-TNF therapy during admission has increased between 2004 and 2014. Surgery during admission was associated with men and at 1 year with men, younger age and non-white ethnicity. <h3>Disclosure of Interest</h3> J. Rees Grant/research support from: £10,000 from Merck Sharp and Dome (MSD) to contribute to costs of HES access, J. Mytton: None Declared, F. Evison: None Declared, P. Patel: None Declared, N. Trudgill: None Declared
Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).
Authors: Kavita Raj, Maadh Aldouri, Aloysius Ho, Antonio Pagliuca, Stephen Devereux, Ghulam Mufti
Journal: Blood (2004)
Evidence-Based Medicine (EBM) Order Set Improves the Management of Patients with Sickle Cell Disease (SCD) Presenting with Severe Acute Pain Episode to the Emergency Room (ER): A Single Center Experience.
Authors: Laura Winslow, Elum Eseoghene, Jack Starmer, John P. Greer, Friedrich Schuening, Leah-anne Owen, Melissa Rhodes, Anne Neff, Madan Jagasia, Adetola A. Kassim
Journal: Blood (2007)
A Retrospective Analysis of 70 Cases of Transient Leukemia (TL) in Neonates with Down Syndrome (DS).
Authors: Hideki Muramatsu, Nobuhiro Watanabe, Kimikazu Matsumoto, Tomohiko Nakamura, Junichi Mimaya, Chizuko Suzuki, Seiji Kojima, Koji Kato
Journal: Blood (2006)